P03-132 - Risperidone and olanzapine in treatment of delusional disorders

详细信息    查看全文

• 作者：N. Zivkovic¹ ; B. Bajovic² ; G. Djokic² ; D. Pavicevic² ; M. Nenadovic²
• 刊名：European Psychiatry
• 出版年：2011
• 出版时间：2011
• 年：2011
• 卷：26
• 期：supp_S1
• 页码：1301
• 全文大小：1K

文摘

Delusional disorders are severe psychotic disorders with characteristic non-bizarre delusions often organized in permanent delusional system.

Aim

To estimate efficacy of risperidone and olanzapine in treatment of DD.

Methods

135 patients with DD were divided into Haloperidol-control (41), Risperidone (49) and Olanzapine group (45 patients). Patients were observed for 6 months according to protocol, which included PANSS Scale and CGI1-4 Scale. Control group was treated with haloperidol 5-30 mg/24 h. Experimental groups were treated with risperidone 2-6 mg/24 h and olanzapine 10-20 mg/24 h.

Results

Pretrial PANSS score was 57.28 in risperidone(R), 60.47 in olanzapine(O) and 58.45 in control(H) group. PANSS score after 180 days was 34.32 in R, 35.58 in O and 37.97 in H group. There was no statistical difference in pretrial scores for PANSS (p = 0.691), CGI1 (p = 0.733), CGI2 (p = 1.000), and CGI3 (p = 1.000) scores. There was statistical significance in PANSS and CGI1-4 score reduction after 180 days in all groups (p = 0.000). There was no statistical difference in PANSS score reduction between R and H (p = 0.114) and O and H group (p = 0.136). CGI1-4 scores reduction: CGI1, Rvs.H, p = 0.019 and Ovs.H, p = 0.032 with high statistical significance; CGI2, Rvs.H, p = 0.153 and Ovs.H, p = 0.179 with no statistical significance; CGI3, Rvs.H, p = 0.183 and Ovs.H, p = 0.161 with no statistical significance; CGI4, Rvs.H, p = 0.000 and Ovs.H, p = 0.000 with high statistical significance. Adverse effects were significantly lower in Risperidone (21.42 % ) and Olanzapine (21.81 % ) than in Haloperidol (57.5 % ) group.

Conclusion

Risperidone and Olanzapine have slightly better efficacy in treatment of DD comparing to haloperidol, with statisticaly significant lower adverse effects rate.